Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AdvanTIG-203: Ociperlimab + Tislelizumab in 2L ESCC
NCT04732494Phase 2Completed
- Sponsor
- BeiGene
- Start
- Mar 2021
- Primary completion
- Feb 2023
- Modality
- IgG Antibodies, Immune Checkpoint Inhibitors
- Countries
- 6
01
Overview
A Phase 2 trial of ociperlimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene. Started Mar 2021; status: completed.
02
Drugs
ociperlimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT04732494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04732494.